N-of-One is a molecular decision support company providing clinicians with the most concise and clinically meaningful interpretation of molecular test results.
Concord, MA
Joined January 2010
- Tweets61
- Following33
- Followers200
- Likes47
Register now for GEN’s webinar July 16 at 11 am ET for a panel of diverse experts led by N-of-One (A QIAGEN Company) Solutions Manager Kelly Sullivan discussing assessing the validity of #biomarkers to inform #drugdevelopment and potential combo therapies: bit.ly/2YejILb
N-of-One retweeted
We’re excited for our first year with @NofOne at #ASCO19! Stop by QIAGEN booth 24103 to learn about @NofOne’s molecular decision support services #PrecisionOncology fal.cn/AcbV
N-of-One retweeted
@QIAGEN and @NofOne proudly present a joint webinar about finding the right precision medicine solution for your clinical #NGS testing lab today. Register now: fal.cn/Avs4
N-of-One's Dr. Kelly Sullivan explains “comprehensive #biomarker analysis is about narrowing & expanding the pool of eligible patients at the same time" re: combination biomarkers for drug development in #precisiononcology in recent @GENbio piece: bit.ly/2YatL3B
Strategic advisor Chris Cournoyer in recent @ClinicalOMICs article on #BigData & #ClinicalGenomics: “There’s a big data normalization problem. Big data sits in silos across any hospital system.” Read more on how expanding datasets will affect the landscape bit.ly/2XV86MD
ICYMI: Our own CSO Sheryl Elkin on a panel this morning at #PMWC2019, led by Sean Scott of @QIAGEN, discussing the current state of molecular test interpretation and reporting, and how real-world data can be leveraged in #precisionmedicine
As part of the @GENbio Magazine relaunch, there is a great article covering the high stakes in #drugdevelopment for #precisionmedicine, featuring our Chief Scientific Officer, Dr. Sheryl Elkin: bit.ly/2SOPZG9
N-of-One retweeted
We are pleased to announce the acquisition of @NofOne to expand our clinical bioinformatics capabilities in molecular oncology decision support. Their Insights reporting tools and MarkerMine database will be integrated into our QCI portfolio.
corporate.qiagen.com/newsroo… – at Hilden, Deutschland
Head on over to room 303AB at #AMP2018 Corporate Workshop Day for a discussion of the complexities around making the right calls in #PrecisionMedicine
If you’re attending #AMP2018 Corporate Workshop Day, be sure not to miss “Helping Pathologists Make the Right Calls in #PrecisionMedicine” at 4:00 pm in room 303AB
Article by N-of-One science & business leaders from @NatureBiotech "Expert curation is currently the only approach that provides a consistent and accurate clinical interpretation that is backed by defendable and transparent reason and evidence": go.nature.com/2nfzHrN
From @GENbio: Sequencing Circulating Tumor DNA Can Provide a More Complete Molecular Picture bit.ly/2O9yUEM
Honored to be named among the “top of mind" #precisionmedicine vendors by @KLASresearch. From @HealthITNews bit.ly/2N6f7VC "Soon precision medicine may be considered the standard of care... a small # of precision med vendors have high mindshare among healthcare provider
From @STATNews on the barriers to genomic testing: Of more than 160 oncologists surveyed about #precisionmedicine and genomic testing, "One-third of respondents said they wait 15 days or more to receive test results.": bit.ly/2tblLT6
Webinar Thurs 6/21 2pm Eastern: Join our panel of industry leaders and @BioPharmaDive as they explore how molecular #biomarkers are driving #companiondiagnostics, the implications for expanding #molecularbiomarker profiles in the future, and much more. bit.ly/2K0wUw7
If you're attending @BIOConvention, be sure to stop by the Company Presentations at 3:15 pm today to watch our VP of Strategy & Solutions Management present on how analysis of real-world molecular data empowers the drug lifecycle #BIO2018 #BioInternationalConvention2018
Our CEO discusses how AI could fit into #precisionmedicine, & why it’s not ready for prime time yet (pg 46): bit.ly/2Is7QAI
“We went from AI winning at Jeopardy, to suddenly wanting it to provide information for highly targeted cancer care. That’s too far, too fast."
